论文部分内容阅读
应用流式细胞分析技术（ＦＣＭ）对４５例有无淋巴结转移乳腺癌的转移抑制基因ｎｍ２３及ＣＤ４４的基因表达和ＤＮＡ倍体进行了定量检测及综合分析。结果表明：乳腺癌淋巴结转移阳性的ＤＮＡ异倍体率６６．６％（２０／３０）高于阴性组４６．７％（７／１５），Ｐ＜０．０５；其增殖活性阳性组ＰＩ＝２６．９±５．３，阴性组ＰＩ＝２１．５±４．９。４５例转移抑制基因ｎｍ２３表达值范围０．８８～１．２９（ＦＩ＝１．２３±０．４３），淋转阳性组ＦＩ＝１．０９±０．１８，低于阴性组ＦＩ＝１．２６±０．２９，Ｐ＜０．０１。ＣＤ４４前组表达阳性率高于后组，分别为７３．３％和４０．０％，两组有显著差异，研究提示：１）ｎｍ２３，ＣＤ４４与乳腺癌淋巴结转移关系最为密切；２）以ｎｍ２３和ＣＤ４４以及ＤＮＡ倍体多参数综合评价乳腺癌的转移优于单项指标
Flow cytometric analysis (FCM) was used to quantitatively analyze and comprehensively analyze the gene expression and DNA ploidy of metastasis suppressor gene nm23 and CD44 in 45 patients with or without lymph node metastasis. The results showed that the rate of DNA aneuploidy with positive lymph node metastasis in breast cancer was 66.6%(20/30) higher than that in negative group(46.7%, 7/15), P<0.05; 26.9±5.3, PI in the negative group was 21.5±4.9. The expression of metastasis suppressor gene nm23 in 45 cases ranged from 0.88 to 1.29 (FI=1.23±0.43). The positive group FI was 1.09±0.18, which was lower than the negative group FI=1.26±0.29, P<0.01. The positive rate of CD44 in the pre-group was higher than that in the latter group (73.3% and 40.0% respectively). There was a significant difference between the two groups. The study suggested that: 1) nm23, CD44 are most closely related to lymph node metastasis in breast cancer; 2) to nm23 And CD44 and DNA ploidy multi-parameter comprehensive evaluation of breast cancer metastasis better than single index